Therapeutic Research

Abstract

Background：Bile acids（BA）in the colon have a dual action as osmotic and stimulant agents. Inhibition of the ileal BA transporter reduces the ileal absorption of BA, increasing the content of BA in the colon, thereby stimulating colonic secretion and mobility. Newer agent such as elobixibat, an inhibitor of the ileal BA transporter, have proven beneficial in chronic constipation. In addition to their role as detergents facilitating dietary lipid absorption, BA modulate various metabolic events after binding to specific BA receptors such as the farnesoid X receptor （FXR）and the G‒protein‒coupled receptor 5（TGR5）. Thus, BA regulate lipid, carbohydrate and energy metabolism. The present study aimed to evaluate metabolic effects of elobixibat in patients with diabetes complicated with chronic constipation（CC）.　　Methods：Sixteen diabetic patients complicated with CC, mean age 75 years, were orally administered elobixibat 5‒15 mg for 3 months. In addition to FBS, HbA1c, LDL‒C, HDL‒C, TG, body weight were measured before and after elobixibat treatment.　　Results：During the study period of 3 months, FBS, HbA1c, LDL‒C, HDL‒C showed significant improvement. But there were not significant reduction of TG and body weight.　　Conclusion：The observation suggests that elobixibat proves beneficial in patients with diabetes complicated with CC.